Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex. A multicenter, double-blind, placebo-controlled trial.

@article{Gottlieb1991ResponseTT,
  title={Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex. A multicenter, double-blind, placebo-controlled trial.},
  author={Michael S. Gottlieb and Robert A Zackin and Michaela Fiala and David H. Henry and Anthony J Marcel and Kathryn Combs and Jeffrey Vieira and Howard A. Liebman and Lawrence A. Cone and Ken Hillman},
  journal={Annals of internal medicine},
  year={1991},
  volume={115 2},
  pages={84-91}
}
OBJECTIVE To determine if a 6-month course of therapy with IMREG-1, a leukocyte-derived immunomodulator, slows disease progression in patients with AIDS-related complex. DESIGN Randomized, double-blind trial. SETTING Five academic- and three community-based clinics. PATIENTS Immunocompromised patients (143) with HIV. INTERVENTIONS IMREG-1 or placebo every 2 weeks (13 doses). MAIN RESULTS Twelve of forty-eight patients on placebo and 5 of 95 patients on IMREG-1 experienced adverse… CONTINUE READING